Paul Rennert

Winter Finch Forecast 2025-2026 - FINCH RESEARCH NETWORK By Tyler Hoar Featured Post Photo: ©David Turgeon GENERAL FORECAST It looks to be a flight year for many species in Eastern Canada. With mostly very poor crops in the boreal forest from central Quebec...

birders---> maybe a good winter coming for northern finches and friends

finchnetwork.org/winter-finch...

#birders #birding #massbird

Color wheel test was fascinating

'As urgent and relevant today as it ever was': The radical manifesto hidden in Georges Seurat's 1884 masterpiece Georges Seurat's once-mocked painting Bathers at Asnières is both an "exquisite distillation of the very essence of summer" and "a modern wonder in the art of seeing".

lovely writeup at BBC #Seurat bbc.com/culture/arti...

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger — SugarCone Biotech A post-ASCO update on tumor targets DLL3, B7H3 and HER3 July 2025 Paul D Rennert, SugarCone Biotech LLC Introduction: DLL3, B7H3 and HER3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse t

target prosecution like this bispecific is a delicate dance between hoped-for efficacy and avoided toxicity ... the EGFRxHER3 pair is a good choice. Why? see here ... sugarconebiotech.com/insights/tar...

Bristol's third pivotal iza-bren study

A very interesting bispecific ADC highlighted today by
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune

This campaign needs you now Ban the over-use of single use plastics.

odd dynamic between clean energy needs and protecting ocean/avian ecosystems

hard to choose a side? yep...

chng.it/ThgpyJY2Pw

Mars, duh.

reminds me to share a landscape peak into advanced therapies - CAR-T and bispecifics - in the autoimmune and inflammation space

for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially restricted by complex m...

Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR

www.thelancet.com/journals/lan...

Concentra goes shopping again, adds CARGO to its market basket
finance.yahoo.com/news/cargo-t...

Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos

HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights

In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.

YouTube video by NuttyRiv3r 15. The Wheel -} Wharf Rat - Grateful Dead - 5/7/77 Boston Garden, Boston, MA - U31DoD 2012 Edition

tgif.
goosebumps at this Wharf Rat, starts @ 10:28
www.youtube.com/watch?v=I1FV...
the wheel is nice too, but man... 'i got up and wandered'

Good things come in 3s — SugarCone Biotech DLL3, B7H3 and Her3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attackin...

quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue

www.sugarconebiotech.com/insights/goo...

June snacks

Remarkable - Swallow-Tailed Kites are using a highly localized cicada emergence as an excuse to hang around and possibly nest in Mashpee MA, way north of their closest haunts in N.Carolina and FL #birding #birdblue

A quick note of thanks to Esobiotec's management and Board of Directors as the AstraZeneca acquisition is now completed. Our job is done with this happy exit, and so the current Board, myself included, disperses. Its a bittersweet moment for me. #biotech #biosky

www.astrazeneca.com/media-centre...

Last Boat to Tangier

and here's a bispecific landscape update from the analysts at sugarconebiotech.com

Novel bispecific antibodies – Part 2 – immunology, asthma and atopic dermatitis — SugarCone Biotech In 1986 - nearly 40 years ago - the first antibody therapy was FDA-approved: muromonab-CD3 (Orthoclone OKT3®), a murine monoclonal antibody targeting human CD3 expressed on T cells. This therapy was u...

ln early March I talked about the bispecific antibody landscape in IAI, specifically for atopic dermatitis and asthma. This remains a red hot area #biosky #biotech ... and we've added analysts to keep up the pace. See sugarconebiotech.com/insights/nov...

#biotech #biosky

Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights

Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights

BeiGene bows out of TIGIT AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.

Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms

Beigene news via #ApexOnco

www.oncologypipeline.com/apexonco/bei...

YouTube video by Jack Straw From Wichita Grateful Dead - Memorial Coliseum (Tuscaloosa, AL) 05/17/1977 (Complete Show)

haven't listened to this '77 very much, it's blistering

www.youtube.com/watch?v=wPgE...

Aleta’s Novel T Cell Engagers — SugarCone Biotech Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...

omg it worked! #bispecifics #oncology #Tcells

www.sugarconebiotech.com/insights/ale... cc www.aletabio.com

Aleta’s Novel T Cell Engagers — Aleta Biotherapeutics By Paul Rennert Aleta’s CSO and Co-Founder Paul Rennert talks about the company’s recent announcement that their scientists created, characterized, and validated novel classes of Immune Cell Engager...

T CELL ENGAGER PROTEINS WITH BUILT IN COSTIMULATORY DOMAINS THAT TURN TUMOR CELLS INTO IMMUNE CELL MIMICS AND TRIGGER IMMUNE SYNAPSE SIGNALING ...

www.aletabio.com/blog-1-1/ale...

@BioAleta

Aleta’s Novel T Cell Engagers — SugarCone Biotech Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...

Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ...

www.sugarconebiotech.com/insights/ale...

proprietary technology that works just as well with CAR T engager proteins

#aletabio #bispecifics #CARTcells

Whoa #biotech

$CRGX implodes.